IPO Trending
REMUSSME / NSEListed

Remus Pharmaceuticals Limited

Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.

₹1,150 - ₹1,22961.53x sub
Listed Price1711.25
Listing Gain+39.24%
FinancialsBalance sheet and operational figures in Crores
Metric Breakdown

Revenue

Latest (Mar 2020)1276.89 Cr
Growth-62.0%
Revenue Trend (₹ in Crores)
0.01.3k2.6k3.9kDec 2022Mar 2022Mar 2021Mar 2020
PeriodRev (Cr)PAT (Cr)AssetsDebt
Mar 20201,276.8981.16530.3635.93
Mar 20211,922.45102.581,104.9627.89
Mar 20222,543.71338.571,590.9319.17
Dec 20223,361.20643.903,352.96947.45
Key Performance Indicators (KPIs)
PeriodEPSROEROCEP/E (Pre)P/E (Post)
Values33.8671.44%69.99%21.090